Navigation Links
Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2
Date:5/23/2013

s muestran que las observaciones anteriores se pueden replicar de forma prospectiva, y que una aproximación híbrida iFR/FFR puede proporcionar un acuerdo superior a un 90% con FFR al tiempo que ahorra el uso del agente hiperémico en más de la mitad de los pacientes".

Los resultados de ADVISE II reproducidos antes de las publicaciones retrospectivas iFR® demostraron que el uso del flujo de trabajo Hybrid iFR®/FFR proporcionó un acuerdo de clasificación general con un FFR en más del 90% de los pacientes que participaron en el estudio, a la vez que evitó a más del 50% de dichos pacientes la administración de fármacos hiperémicos. De hecho, el análisis preliminar mostró un 91,5% de acuerdo con FFR y un 71,5% de ahorros de fármacos hiperémicos por lesión. Los pacientes de ADVISE II fueron reclutados de más de 40 centros de Estados Unidos y Europa, y todos los análisis fueron realizados con operadores a ciegas de valores iFR® que fueron calculados offline en un laboratorio central independiente en Rótterdam, Países Bajos.

También se presentaron esta semana los primeros 392 casos en tiempo real desarrollados en vivo en el cath lab de más de 20 centros de Europa, Japón y Sudáfrica que están ahora equipados con el software iFR®. Esos resultados confirmaron los resultados anteriores y los resultados preliminares ADVISE II presentados en EuroPCR.

"Después de usar iFR en la práctica clínica mundial, su simplicidad es claramente su fortaleza. En un cath lab ocupado, ahorrar tiempo es importante y los resultados en mi experiencia han sido consistentes y útiles clínicamente", comentó Andrew Sharp , MD, Interventional Cardiologist del Royal Devon & Exeter Hospital, Exeter, Reino Unido. "Una vez
'/>"/>

SOURCE Volcano Corporation
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Volcano Corporation Presentation At JMP Securities Conference To Be Webcast
2. Volcano to Highlight its Leadership in Precision Guided Therapy at EuroPCR 2012
3. Volcano Corporation Presentation At Jefferies Conference To Be Webcast
4. Volcano Corporation Presentation at Wells Fargo Conference to be Webcast
5. Volcano Corporation Schedules Second Quarter Conference Call, Webcast
6. Volcano Corporation Reports 13 Percent Growth In Second Quarter Revenues; FFR Disposable Revenues Increase 38 Percent
7. Volcano Corporation Presentation At Canaccord Genuity Conference To Be Webcast
8. FAME 2 Published in the New England Journal of Medicine, Volcano participates in the $84M NIH-Sponsored ISCHEMIA Trial
9. Volcano Corporation Presentation At Stifel Nicolaus Conference To Be Webcast
10. Volcano Announces Previous St. Jude Medical Products Infringe Volcano Patent and Jury Verdicts in Patent Trials with St. Jude Medical
11. Volcano Corporation Schedules Third Quarter Conference Call, Webcast
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/31/2014)... , Oct. 31, 2014  Australian biopharmaceutical company ... ® (nanoparticle albumin-bound paclitaxel) in combination with gemcitabine, ... for patients with metastatic pancreatic cancer from 1 November. ... pancreatic cancer is the 5 th most common ... of all cancer deaths, with the lowest 5-year survival ...
(Date:10/31/2014)... 31, 2014 Investor-Edge has initiated ... NSPH ), Isis Pharmaceuticals Inc. (NASDAQ: ... ), ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD ), ... these five companies can be accessed at: http://investor-edge.com/register ... NASDAQ Composite ended at 4,566.14, up 0.37%, the Dow ...
(Date:10/31/2014)... Australia and BARCELONA , October ... Ltd (Multigate) was found to infringe two Australian patents of ... for sale in Australia safety IV ... 17.10.14 in Federal Court of Australia ... http://www.austlii.edu.au/au/cases/cth/FCA/2014/1110.html . In the detailed judgment, ...
Breaking Medicine Technology:Specialised Therapeutics Australia Announces Breakthrough Cancer Drug Abraxane(R) to be PBS Listed for Metastatic Pancreatic Cancer 2Specialised Therapeutics Australia Announces Breakthrough Cancer Drug Abraxane(R) to be PBS Listed for Metastatic Pancreatic Cancer 3Specialised Therapeutics Australia Announces Breakthrough Cancer Drug Abraxane(R) to be PBS Listed for Metastatic Pancreatic Cancer 4Specialised Therapeutics Australia Announces Breakthrough Cancer Drug Abraxane(R) to be PBS Listed for Metastatic Pancreatic Cancer 5Specialised Therapeutics Australia Announces Breakthrough Cancer Drug Abraxane(R) to be PBS Listed for Metastatic Pancreatic Cancer 6Specialised Therapeutics Australia Announces Breakthrough Cancer Drug Abraxane(R) to be PBS Listed for Metastatic Pancreatic Cancer 7Specialised Therapeutics Australia Announces Breakthrough Cancer Drug Abraxane(R) to be PBS Listed for Metastatic Pancreatic Cancer 8Momentum Indicators for Biotech Stocks -- Nanosphere, Isis Pharma, Halozyme Therapeutics, ACADIA Pharma, and Synta Pharma 2Momentum Indicators for Biotech Stocks -- Nanosphere, Isis Pharma, Halozyme Therapeutics, ACADIA Pharma, and Synta Pharma 3Momentum Indicators for Biotech Stocks -- Nanosphere, Isis Pharma, Halozyme Therapeutics, ACADIA Pharma, and Synta Pharma 4Momentum Indicators for Biotech Stocks -- Nanosphere, Isis Pharma, Halozyme Therapeutics, ACADIA Pharma, and Synta Pharma 5B. Braun Wins Patent Disputes Against Poly Medicure Ltd's Australian Distributor Multigate Medical Devices Pty. Ltd. and Spanish Distributor Dextromédica S. L. 2
(Date:10/31/2014)... October 31, 2014 Springboard Biodiesel, ... its small scale BioPro™ biodiesel processors, announced on ... further improve the performance and efficiency of small-scale ... GL95/MC12/BD380 trio will recover more than 99% ... with the glycerin by-product produced while making biodiesel. ...
(Date:10/31/2014)... The Prevention Research Center for Healthy Neighborhoods (PRCHN) ... is a key player in nearly $13.32 million ... in Northeast Ohio. , The Centers for Disease ... for $4.35 million over five years. The funds ... testing, and disseminating individual, environmental, and policy interventions ...
(Date:10/31/2014)... Denver, Colorado (PRWEB) October 31, 2014 The ... program was created by Alexander Lynch, whose father suffered from ... through a dramatic moment, caused by his father's disease. His ... crisis. That was the crucial moment when the author of ... help his dad. , The Memory Healer program is ...
(Date:10/31/2014)... October 31, 2014 Monica Williams-Murphy ... knows all too well the chaos that can occur ... end-of-life. “The vast majority of Americans who come into ... lives are completely unprepared for the moment and so ... app can serve as a catalyst for a family ...
(Date:10/31/2014)... 2014 At the start of 2014, ... escaping carbon monoxide poisoning in their homes. Now, as ... one family-owned, Missouri-based heating and cooling company is taking ... families start the home heating season with the assurance ... , Beginning Nov. 1, 2014, E and Q Heating ...
Breaking Medicine News(10 mins):Health News:Springboard Biodiesel Announces Release of New and Unique Methanol Recovery and Glycerin Treatment Equipment 2Health News:Springboard Biodiesel Announces Release of New and Unique Methanol Recovery and Glycerin Treatment Equipment 3Health News:Case Western Reserve, Cuyahoga County, YMCA of greater Cleveland: Public health grants 2Health News:Case Western Reserve, Cuyahoga County, YMCA of greater Cleveland: Public health grants 3Health News:"Memory Healer" Review Reveals a New Natural Remedy Guide for Managing Memory Loss 2Health News:This Thanksgiving or Christmas Family Gathering, Use The New App ListStuffFast to Start "The Conversation" With a Parent That Has No Plan For End-of-Life 2Health News:This Thanksgiving or Christmas Family Gathering, Use The New App ListStuffFast to Start "The Conversation" With a Parent That Has No Plan For End-of-Life 3Health News:Many Homeowners Missing Key Safety Risks with Home Heating;Missouri-based Company E and Q Announces New Safety Check 2Health News:Many Homeowners Missing Key Safety Risks with Home Heating;Missouri-based Company E and Q Announces New Safety Check 3
... antidepressant plus naltrexone improves odds of not drinking, researchers ... treatment with the antidepressant Zoloft (sertraline) and the alcoholism ... major depression and alcohol dependence will be able to ... of 170 patients found that 54 percent of those ...
... microarray analysis detects more abnormalities , MONDAY, March ... test is better at detecting abnormalities that predispose a ... has determined. , Researchers offered about 933 people aged ... with an autism spectrum disorder three genetic tests: G-banded ...
... ... their own Trillion Dollar Question: How do we increase employee productivity and decrease ... maker of Sweat365.com, unveils “The Healthy Corp” a breakthrough product that RE-DEFINES “Corporate ... ...
... HONG KONG , March ... or "the Group"; Stock Code: 801), China,s ... announce,today that the Group,s shareholders (the "Shareholders") have approved ... special resolution as,proposed by the board of directors ("the ...
... has named Fred Hassan as chairman of the Board of Directors and has named Brent Saunders as chief executive officer and appointed him to the Board of Directors, ... , ... ... ...
... Food and Chemical Sensitivity , announced that Philip Voluck has joined the firm and is establishing a new company that will be known as PreviMedica Lifestyle Medicine ... ... ... ...
Cached Medicine News:Health News:Newer Genetic Test for Autism More Effective 2Health News:Newer Genetic Test for Autism More Effective 3Health News:Konamoxt, Inc. Redefines Corporate Wellness with The Healthy Corp, a Customizable Corporate Wellness Platform 2Health News:Konamoxt, Inc. Redefines Corporate Wellness with The Healthy Corp, a Customizable Corporate Wellness Platform 3Health News:Golden Meditech Shareholders Approves of Name Change 2Health News:Golden Meditech Shareholders Approves of Name Change 3Health News:Bausch + Lomb Names Fred Hassan as Chairman, Brent Saunders as Chief Executive Officer 2Health News:Bausch + Lomb Names Fred Hassan as Chairman, Brent Saunders as Chief Executive Officer 3Health News:Bausch + Lomb Names Fred Hassan as Chairman, Brent Saunders as Chief Executive Officer 4Health News:Cell Science Systems Recruits Seasoned Executive to Head New Lifestyle Medicine & Nutritional Solution for Health Care Professionals 2Health News:Cell Science Systems Recruits Seasoned Executive to Head New Lifestyle Medicine & Nutritional Solution for Health Care Professionals 3Health News:Cell Science Systems Recruits Seasoned Executive to Head New Lifestyle Medicine & Nutritional Solution for Health Care Professionals 4
... Suture ENDO CLIP 5 mm clip ... applier is designed for introduction and ... Suture trocar sleeve, or larger with ... overall length of the shaft is ...
... Lock Clip is designed with opposing male/female ... clip retention and improved hemostasis., ,By ... a 20 percent greater angle allowing for ... ,The Reflex® ELC has an automatic, direct ...
Insert only, Pilling-Weck medium clip size...
Pilling-Weck, medium clip size, 10mm, rotatable take apart...
Medicine Products: